GBD 2021 Antimicrobial Resistance Collaborators Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050. Lancet 404, 1199–1226 (2024).
Denning, D. W. Global incidence and mortality of severe fungal disease. Lancet Infect. Dis. 24, e428–e438 (2024).
Zhang, F. et al. A marine microbiome antifungal targets urgent-threat drug-resistant fungi. Science 370, 974–978 (2020).
Fisher, M. C. et al. Tackling the emerging threat of antifungal resistance to human health. Nat. Rev. Microbiol. 20, 557–571 (2022).
Hancock, R. E. W. & Sahl, H.-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551–1557 (2006).
Homer, J. A., Johnson, R. M., Koelln, R. A., Moorhouse, A. D. & Moses, J. E. Strategic re-engineering of antibiotics. Nat. Rev. Bioeng. 3, 213–229 (2025).
Fisher, M. C., Hawkins, N. J., Sanglard, D. & Gurr, S. J. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science 360, 739–742 (2018).
Ho, C. S. et al. Antimicrobial resistance: a concise update. Lancet Microbe 6, 100947 (2025).
Xiong, M. et al. Helical antimicrobial polypeptides with radial amphiphilicity. Proc. Natl Acad. Sci. USA 112, 13155–13160 (2015).
Li, X. et al. Supramolecular antibacterial materials for combatting antibiotic resistance. Adv. Mater. 31, e1805092 (2019).
Kong, H. et al. Development of aromatic-linked diamino acid antimicrobial peptide mimics with low hemolytic toxicity and excellent activity against methicillin-resistant Staphylococcus aureus (MRSA). J. Med. Chem. 66, 7756–7771 (2023).
Ghosh, C., Sarkar, P., Issa, R. & Haldar, J. Alternatives to conventional antibiotics in the era of antimicrobial resistance. Trends Microbiol. 27, 323–338 (2019).
Lehar, J. et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27, 659–666 (2009).
Brochado, A. R. et al. Species-specific activity of antibacterial drug combinations. Nature 559, 259–263 (2018).
Si, Z., Pethe, K. & Chan-Park, M. B. Chemical basis of combination therapy to combat antibiotic resistance. JACS Au 3, 276–292 (2023).
Ding, X. et al. A macromolecule reversing antibiotic resistance phenotype and repurposing drugs as potent antibiotics. Adv. Sci. 7, 2001374 (2020).
Si, Z. et al. A glycosylated cationic block poly(β-peptide) reverses intrinsic antibiotic resistance in all ESKAPE Gram-negative bacteria. Angew. Chem. Int. Ed. 59, 6819–6826 (2020).
Gong, Y., Wang, H. & Sun, J. AMP-mimetic antimicrobial polymer-involved synergic therapy with various coagents for improved efficiency. Biomacromolecules 25, 4619–4638 (2024).
Schmidt, N. W. et al. Engineering persister-specific antibiotics with synergistic antimicrobial functions. ACS Nano 8, 8786–8793 (2014).
Bai, H. et al. A supramolecular antibiotic switch for antibacterial regulation. Angew. Chem. Int. Ed. 54, 13208–13213 (2015).
Liu, L. et al. Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat. Nanotechnol. 4, 457–463 (2009).
Jiang, W. et al. Peptide-mimicking poly(2-oxazoline)s possessing potent antifungal activity and BBB penetrating property to treat invasive infections and meningitis. J. Am. Chem. Soc. 145, 25753–25765 (2023).
Zhou, M. et al. A dual-targeting antifungal is effective against multidrug-resistant human fungal pathogens. Nat. Microbiol 9, 1325–1339 (2024).
Zhang, X. et al. Development of lipo-γ-AA peptides as potent antifungal agents. J. Med. Chem. 65, 8029–8039 (2022).
Liu, F. et al. Synergistic wall digestion and cuproptosis against fungal infections using lywallzyme-induced self-assembly of metal-phenolic nanoflowers. Nat. Commun. 15, 9004 (2024).
Chen, L. et al. Brain glucose induces tolerance of Cryptococcus neoformans to amphotericin B during meningitis. Nat. Microbiol 9, 346–358 (2024).
Maji, A. et al. Tuning sterol extraction kinetics yields a renal-sparing polyene antifungal. Nature 623, 1079–1085 (2023).
Bennett, J. E. et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N. Engl. J. Med. 301, 126–131 (1979).
Beck, A., Goetsch, L., Dumontet, C. & Corvaia, N. Strategies and challenges for the next generation of antibody–drug conjugates. Nat. Rev. Drug Discov. 16, 315–337 (2017).
Li, X., et al. Multifunctional nanoparticle-mediated combining therapy for human diseases. Signal Transduct. Target. Ther. 9, 1 (2024).
Detappe, A. et al. Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma. Nat. Nanotechnol. 18, 184–192 (2023).
Sofias, A. M. & Lammers, T. Multidrug nanomedicine. Nat. Nanotechnol. 18, 104–106 (2023).
Cheng, T. et al. Green tea catechin-based complex micelles combined with doxorubicin to overcome cardiotoxicity and multidrug resistance. Theranostics 6, 1277–1292 (2016).
Lancet, J. E. et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 8, e481–e491 (2021).
Lancet, J. E. et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J. Clin. Oncol. 36, 2684–2692 (2018).
Li, Y. et al. Co-delivery of precisely prescribed multi-prodrug combination by an engineered nanocarrier enables efficient individualized cancer chemotherapy. Adv. Mater. 34, e2110490 (2022).
Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y. & Wu, X. Y. Nanomedicine of synergistic drug combinations for cancer therapy—strategies and perspectives. J. Control. Release 240, 489–503 (2016).
Zhou, M. et al. Poly(2-oxazoline)-based functional peptide mimics: eradicating MRSA infections and persisters while alleviating antimicrobial resistance. Angew. Chem. Int. Ed. 59, 6412–6419 (2020).
Tauhardt, L., Kempe, K., Gottschaldt, M. & Schubert, U. S. Poly(2-oxazoline) functionalized surfaces: from modification to application. Chem. Soc. Rev. 42, 7998–8011 (2013).
Lorson, T. et al. Poly(2-oxazoline)s based biomaterials: a comprehensive and critical update. Biomaterials 178, 204–280 (2018).
Zhu, Y., Yang, B., Chen, S. & Du, J. Polymer vesicles: mechanism, preparation, application, and responsive behavior. Prog. Polym. Sci. 64, 1–22 (2017).
Cui, H., Webber, M. J. & Stupp, S. I. Self-assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials. Biopolymers 94, 1–18 (2010).
Zhang, Z., Ai, S., Yang, Z. & Li, X. Peptide-based supramolecular hydrogels for local drug delivery. Adv. Drug Deliv. Rev. 174, 482–503 (2021).
Walker, L. et al. The viscoelastic properties of the fungal cell wall allow traffic of AmBisome as intact liposome vesicles. mBio 9, e02383-17 (2018).
Colombo, R. & Rich, J. R. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell 40, 1255–1263 (2022).
Yongvongsoontorn, N. et al. Carrier-enhanced anticancer efficacy of sunitinib-loaded green tea-based micellar nanocomplex beyond tumor-targeted delivery. ACS Nano 13, 7591–7602 (2019).
Wang, C. H., Wang, W. T. & Hsiue, G. H. Development of polyion complex micelles for encapsulating and delivering amphotericin B. Biomaterials 30, 3352–3358 (2009).
Laconde, G., Amblard, M. & Martinez, J. Synthesis of α-amino acid N-carboxyanhydrides. Org. Lett. 23, 6412–6416 (2021).
Dos Reis, T. F., et al. A host defense peptide mimetic, brilacidin, potentiates caspofungin antifungal activity against human pathogenic fungi. Nat. Commun. 14, 2052 (2023).
Davis, S. A. et al. Nontoxic antimicrobials that evade drug resistance. Nat. Chem. Biol. 11, 481–487 (2015).
Wilcock, B. C., Endo, M. M., Uno, B. E. & Burke, M. D. C2′-OH of amphotericin B plays an important role in binding the primary sterol of human cells but not yeast cells. J. Am. Chem. Soc. 135, 8488–8491 (2013).
Liu, Y. -g, et al. NLRP3 inflammasome activation mediates radiation-induced pyroptosis in bone marrow-derived macrophages. Cell Death Dis. 8, e2579 (2017).
Wiradharma, N., Tong, Y. W. & Yang, Y. Y. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect. Biomaterials 30, 3100–3109 (2009).
Jiang, W. et al. Short guanidinium-functionalized poly(2-oxazoline)s displaying potent therapeutic efficacy on drug-resistant fungal infections. Angew. Chem. Int. Ed. 61, e202200778 (2022).
Mukherjee, J., Pirofski, L. A., Scharff, M. D. & Casadevall, A. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. Proc. Natl Acad. Sci. USA 90, 3636–3640 (1993).
Jafari, H. S. et al. Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis. Antimicrob. Agents Chemother. 38, 83–89 (1994).
